drugset
drugset / Trial / NCT06228963

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

NCT06228963 ↗

Phase 2 Recruiting 160 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma

Timeline

Start
2024-03
Primary completion
2026-01
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule — —

Indications

Helicobacter pylori infectious disease gastric mucosa-associated lymphoid tissue lymphoma